PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.76%
EBIT growth below 50% of RVPH's 58.36%. Michael Burry would suspect deeper competitive or cost structure issues.
10.76%
Operating income growth under 50% of RVPH's 58.36%. Michael Burry would be concerned about deeper cost or sales issues.
11.35%
Net income growth under 50% of RVPH's 207.37%. Michael Burry would suspect the firm is falling well behind a key competitor.
31.03%
EPS growth under 50% of RVPH's 851.45%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
31.72%
Diluted EPS growth under 50% of RVPH's 851.45%. Michael Burry would worry about an eroding competitive position or excessive dilution.
29.31%
Slight or no buybacks while RVPH is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
29.44%
Slight or no buyback while RVPH is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
2.31%
OCF growth under 50% of RVPH's 68.55%. Michael Burry might suspect questionable revenue recognition or rising costs.
3.06%
FCF growth under 50% of RVPH's 68.55%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-254578.19%
Negative 10Y OCF/share CAGR while RVPH stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
64.50%
OCF/share CAGR of 64.50% while RVPH is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
73.57%
3Y OCF/share CAGR of 73.57% while RVPH is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
-9976.84%
Negative 10Y net income/share CAGR while RVPH is at 1440.27%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-124.34%
Negative 5Y net income/share CAGR while RVPH is 1440.27%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
76.73%
Below 50% of RVPH's 1440.27%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
1493.31%
Equity/share CAGR of 1493.31% while RVPH is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-38.28%
Negative 5Y equity/share growth while RVPH is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-74.77%
Negative 3Y equity/share growth while RVPH is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.33%
Asset growth of 78.33% while RVPH is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
127.26%
Under 50% of RVPH's 7789.47%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-9.95%
We’re deleveraging while RVPH stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-7.53%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-21.01%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.